Adam33 polymorphisms are associated with COPD and lung function in long-term tobacco smokers

Respiratory Research

Table 3 Estimated* mean pulmonary function measurements for genotypes of SNPs in ADAM33 gene that were associated with COPD.

SNP	Genotype	ppFEV1	p value*	ppFVC	p value*	Ratio	p value*	ppFEF25–75	p value*
rs612709	CT+TT	78.62	0.0135	84.49	0.2610	69.88	0.0044	64.52	0.0015
(Q-1)	CC†	73.72	0.0132	83.36	0.3093	66.42	0.0122	55.00	0.0012
rs3918396	AG+AA	79.08	0.0256	83.85	0.2883	70.35	0.0068	64.84	0.0079
(S1)	GG†	74.17	0.0143	83.93	0.2710	66.69	0.0112	56.00	0.0019
rs528557	CG+CC	75.94	0.2342	84.91	0.8372	68.38	0.0425	59.51	0.1131
(S2)	GG†	74.26	0.1571	83.49	0.6225	66.42	0.1329	55.80	0.1594
rs543749	CA+AA	79.08	0.0083	85.20	0.2085	69.96	0.0050	65.17	0.0009
(V-1)	CC†	73.57	0.0057	83.42	0.2211	66.40	0.0116	54.76	0.0004
rs2787094	CG+GG	76.50	0.1501	85.14	0.3591	68.32	0.1229	60.54	0.0568
(V4)	CC†	73.92	0.1697	83.61	0.5695	66.63	0.1756	55.32	0.0344

COPD: Chronic Obstructive Pulmonary Disease; defined by an FEV1/FVC ratio < 70% and ppFEV₁ < 75% (n = 287). Control group were smokers with an FEV1/FVC ratio ≥ 70% and ppFEV₁ ≥ 80% (n = 311).
ppFEV1: percent predicted Forced Expiratory Volume at the First second.
ppFVC: percent predicted Forced Vital Capacity.
Ratio: FEV1/FVC ratio.
ppFEF25–75: Forced Expiratory Flow 25–75%.
* Generalized linear models, adjusted for sex, age and pack-year smoked. Values in bold are pertinent to all subjects (n = 880).
† Major allele homozygous.

ISSN: 1465-993X